The mechanisms and effects on organ protection of combination of nitric oxide gas and iloprost during cardiopulmonary bypass

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000242

Enrollment

Unknown

Registered

2008-12-23

Start date

2008-12-30

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

isolated atrial septal defects and/or ventricular septal defects with/without pulmonary hypertension

Interventions

NO plus iloprost group:routine CPB plus NO plus iloprost

iloprost group:routine CPB plus iloprost

NO group:routine CPB plus NO

blank control:routine CPB not taking any drugs

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The children weighing 5-15kg with isolated atrial septal defects and/or ventricular septal defects

Exclusion criteria

Exclusion criteria: patients with (1) haemodynamic insability; (2) with coagulation abnormalities; (3) with serious pulmonary infects difficult to control before operation; (4) with serious non-pulmonary infects; (5) associated with other serious non-cardiac lesions or complications; (6) who cannot use nitric oxide gas and iloprost; (7) associated with other cardiac lesions; (8) who dies during operation.

Design outcomes

Primary

Measure	Time frame
elastase;PAF;IL-8;serum creatinine;urine creatinine;blood cell counting and classification;	—

Countries

China

Contacts

Public ContactQi An; Lei Du

anqi8890@163.com+86 028 81812524

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026